Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104805 | 0.79 | AURKA (0.50) | — | |
| SCHEMBL6680537 | 0.77 | NPY5R (0.47) | — | |
| SCHEMBL5106907 | 0.74 | EGFR (0.43) | — | |
| SCHEMBL5105982 | 0.74 | CA12 (0.40) | — | |
| SCHEMBL5107218 | 0.74 | CRHBP (0.33) | CRHBPCRHR2KEAP1NFE2L2 | |
| SCHEMBL11347630 | 0.73 | MAPT (0.41) | CRHBPCRHR2KEAP1NFE2L2IDO1 | |
| SCHEMBL5316367 | 0.73 | CRHBP (0.34) | CRHBPCRHR2KEAP1NFE2L2IDO1 | |
| SCHEMBL5107697 | 0.73 | MEN1 (0.35) | CRHBPCRHR2KEAP1NFE2L2IDO1 | |
| SCHEMBL165738 | 0.72 | ROCK1 (0.45) | — | |
| SCHEMBL5107999 | 0.71 | KMT2A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | claimed |
| EP-1846392-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | Sentinel Oncology Limited (GB) | 2007-10-24 | — | — | EP | claimed |
| WO-2006131835-A2 | HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2006-12-14 | — | — | WO | claimed |
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | SENTINEL ONCOLOGY LIMITED (UK) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234276-A1 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors | HIF1AN, HIF1A, CDK2 | CRHBP 2246/4885CRHR2 2260/4885KEAP1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.